Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

ABSTRACT:

Background

Our objective was to evaluate and compare the effect of abacavir on levels of biomarkers associated with cardiovascular risk.

Methods

In an open-label randomized trial, HIV-infected patients were randomized 1:1 to switch from zidovudine/lamivudine to abacavir/lamivudine or tenofovir/emtricitabine. In the present analysis, we measured levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), E-selectin, and myeloperoxidase (MPO) at baseline and 4, 12, and 48 weeks after randomization. D-dimer and fasting lipids were measured at baseline and weeks 12 and 48. Levels of biomarkers at all time points and changes from baseline were compared across stu

SUBMITTER: Rasmussen TA 

PROVIDER: S-EPMC3204252 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature